猪甲型流感病毒(SwIAV)是具有兽医学意义的病原体。鼻内(IN)疫苗接种有可能减少流感感染。我们研究了用植物来源的纳米颗粒佐剂[Nano11-SwIAV]或与STING激动剂ADU-S100[NanoS100-SwIAV]组合吸附的分裂SwIAVH1N1抗原的功效。常规猪通过IN接种疫苗并用异源SwIAVH1N1-OH7或2009年H1N1大流行病毒攻击。免疫学,在NanoS100-SwIAV疫苗接种中,我们观察到大流行病毒攻击动物的血液和H1N1-OH7攻击动物的气管支气管淋巴结(TBLN)中活化单核细胞的频率增加.在两组病毒攻击的猪中,在引流TBLN的Nano11-SwIAV疫苗接种中观察到IL-17A+和CD49d+IL-17A+细胞毒性淋巴细胞的频率增加。观察到两种基于Nano11的SwIAV疫苗接种物的TBLN和血液中CD49d+IFNγ+CTL的频率增加。接种两种基于Nano11的疫苗的动物在肺和血清IgG中针对异源和异亚型病毒的交叉反应性分泌型IgA上调。然而,在NanoS100-SwIAV疫苗接种中,检测到鼻腔中H1N1大流行病毒的早期轻微减少和SwIAVH1N1-OH7负荷的晚期减少.因此,尽管疫苗和两种攻击病毒之间存在巨大的遗传差异,用NanoS100-SwIAV的IN疫苗接种诱导抗原特异性中等水平的交叉保护性免疫应答。
Swine influenza A viruses (SwIAVs) are pathogens of both veterinary and medical significance. Intranasal (IN) vaccination has the potential to reduce flu infection. We investigated the efficacy of split SwIAV H1N2 antigens adsorbed with a plant origin nanoparticle adjuvant [
Nano11-SwIAV] or in combination with a STING agonist ADU-S100 [NanoS100-SwIAV]. Conventional pigs were vaccinated via IN and challenged with a heterologous SwIAV H1N1-OH7 or 2009 H1N1 pandemic virus. Immunologically, in NanoS100-SwIAV vaccinates, we observed enhanced frequencies of activated monocytes in the blood of the pandemic virus challenged animals and in tracheobronchial lymph nodes (TBLN) of H1N1-OH7 challenged animals. In both groups of the virus challenged pigs, increased frequencies of IL-17A+ and CD49d+IL-17A+ cytotoxic lymphocytes were observed in
Nano11-SwIAV vaccinates in the draining TBLN. Enhanced frequency of CD49d+IFNγ+ CTLs in the TBLN and blood of both the
Nano11-based SwIAV vaccinates was observed. Animals vaccinated with both
Nano11-based vaccines had upregulated cross-reactive secretory IgA in the lungs and serum IgG against heterologous and heterosubtypic viruses. However, in NanoS100-SwIAV vaccinates, a slight early reduction in the H1N1 pandemic virus and a late reduction in the SwIAV H1N1-OH7 load in the nasal passages were detected. Hence, despite vast genetic differences between the vaccine and both the challenge viruses, IN vaccination with NanoS100-SwIAV induced antigen-specific moderate levels of cross-protective immune responses.